BMRN - BioMarin Pharmaceutical Inc.
NASDAQ
->
Healthcare
->
Biotechnology
San Rafael,
United States
Type: Equity
BMRN price evolution
BMRN
| (in millions $) | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $747 | $755.13 | $785.41 | $694.38 |
| Short term investments | $299.58 | $318.68 | $340.43 | $476.58 |
| Net receivables | $637.16 | $633.7 | $572.5 | $610.22 |
| Inventory | $1137.98 | $1107.18 | $1032.16 | $975.55 |
| Total current assets | $2985.01 | $2956.09 | $2955.31 | $2950.12 |
| Long term investments | $620.55 | $611.13 | $548 | $385.78 |
| Property, plant & equipment | $1060.42 | $1066.13 | $1067.16 | $1067.28 |
| Goodwill & intangible assets | $475.85 | $490.9 | $498.68 | $506.54 |
| Total noncurrent assets | $3887.66 | $3885.51 | $3802.86 | $3613.05 |
| Total investments | $920.13 | $929.82 | $888.43 | $862.35 |
| Total assets | $6872.67 | $6841.6 | $6758.16 | $6563.17 |
| Current liabilities | ||||
| Accounts payable | $593.54 | $683.15 | $669.83 | $597.23 |
| Deferred revenue | ||||
| Short long term debt | $494.36 | $493.88 | $493.4 | |
| Total current liabilities | $1087.9 | $1177.02 | $1163.22 | $597.23 |
| Long term debt | $593.61 | $593.1 | $592.59 | $1084.99 |
| Total noncurrent liabilities | $710.96 | $713.03 | $698.04 | $1183.11 |
| Total debt | $1087.96 | $1086.97 | $1085.98 | $1084.99 |
| Total liabilities | $1798.86 | $1890.05 | $1861.27 | $1780.35 |
| Shareholders' equity | ||||
| Retained earnings | -$532.89 | -$621.55 | -$641.93 | -$682.31 |
| Other shareholder equity | -$1.05 | -$28.79 | $6.26 | -$18.62 |
| Total shareholder equity | $5073.82 | $4951.55 | $4896.9 | $4782.83 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $755.13 | $724.53 | $587.28 | $649.16 |
| Short term investments | $318.68 | $567.01 | $426.6 | $416.23 |
| Net receivables | $633.7 | $461.32 | $373.4 | $448.35 |
| Inventory | $1107.18 | $894.08 | $776.67 | $698.55 |
| Total current assets | $2956.09 | $2751.46 | $2274.39 | $2342.22 |
| Long term investments | $611.13 | $333.83 | $507.79 | $285.47 |
| Property, plant & equipment | $1066.13 | $1114.32 | $1035.46 | $1032.47 |
| Goodwill & intangible assets | $490.9 | $534.77 | $584.85 | $613.47 |
| Total noncurrent assets | $3885.51 | $3623.62 | $3728.94 | $3505.8 |
| Total investments | $929.82 | $900.84 | $934.39 | $701.7 |
| Total assets | $6841.6 | $6375.07 | $6003.32 | $5848.02 |
| Current liabilities | ||||
| Accounts payable | $683.15 | $231.24 | $491.59 | $492.55 |
| Deferred revenue | ||||
| Short long term debt | $493.88 | |||
| Total current liabilities | $1177.02 | $588.88 | $539.82 | $492.55 |
| Long term debt | $593.1 | $1083.2 | $1079.08 | $1075.14 |
| Total noncurrent liabilities | $713.03 | $1183.03 | $1192.76 | $1249.47 |
| Total debt | $1086.97 | $1083.02 | $1079.08 | $1075.14 |
| Total liabilities | $1890.05 | $1771.92 | $1732.59 | $1742.02 |
| Shareholders' equity | ||||
| Retained earnings | -$621.55 | -$789.2 | -$925.69 | -$861.61 |
| Other shareholder equity | -$28.79 | -$0.63 | $14.43 | -$16.14 |
| Total shareholder equity | $4951.55 | $4603.16 | $4270.74 | $4106 |
| (in millions $) | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $648.83 | $646.21 | $581.33 | $595.27 |
| Cost of revenue | $125.18 | $135.48 | $124.75 | $128.08 |
| Gross Profit | $523.65 | $510.73 | $456.58 | $467.19 |
| Operating activities | ||||
| Research & development | $204.99 | $206.25 | $191.31 | $177.36 |
| Selling, general & administrative | $225.91 | $275.02 | $223.93 | $215.34 |
| Total operating expenses | $435.19 | $496.51 | $430.92 | $408.32 |
| Operating income | $88.46 | $14.22 | $25.66 | $58.87 |
| Income from continuing operations | ||||
| EBIT | $109.09 | $25.43 | $45.45 | $74.56 |
| Income tax expense | $16.89 | -$1.05 | $1.29 | $14.77 |
| Interest expense | $3.55 | $6.1 | $3.78 | $3.75 |
| Net income | ||||
| Net income | $88.66 | $20.38 | $40.38 | $56.04 |
| Income (for common shares) | $88.66 | $20.38 | $40.38 | $56.04 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $2419.23 | $2096.04 | $1846.28 | $1860.45 |
| Cost of revenue | $514.85 | $483.67 | $470.51 | $524.27 |
| Gross Profit | $1904.37 | $1612.37 | $1375.76 | $1336.18 |
| Operating activities | ||||
| Research & development | $746.77 | $649.61 | $628.79 | $628.12 |
| Selling, general & administrative | $937.29 | $854.01 | $759.38 | $737.67 |
| Total operating expenses | $1746.28 | $1462.81 | $1458.1 | $1372.95 |
| Operating income | $158.1 | $149.56 | -$82.34 | -$36.77 |
| Income from continuing operations | ||||
| EBIT | $205.9 | $165.55 | -$60.01 | -$13.01 |
| Income tax expense | $20.92 | $8.02 | -$11.27 | -$901.42 |
| Interest expense | $17.34 | $15.97 | $15.34 | $29.31 |
| Net income | ||||
| Net income | $167.65 | $141.56 | -$64.08 | $859.1 |
| Income (for common shares) | $167.65 | $141.56 | -$64.08 | $859.1 |
| (in millions $) | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 |
|---|---|---|---|---|
| Net income | $88.66 | $20.38 | $40.38 | $56.04 |
| Operating activities | ||||
| Depreciation | $27.35 | $26.86 | $25.68 | $25.42 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $58.25 | $54.85 | $48.39 | $50.16 |
| Total cash flows from operations | $46.97 | $27.48 | $135.65 | $70.06 |
| Investing activities | ||||
| Capital expenditures | -$16.1 | -$28.92 | -$21.73 | -$21.58 |
| Investments | $9.87 | -$28.27 | -$22.38 | $52.26 |
| Total cash flows from investing | -$14.24 | -$64.96 | -$45.8 | $29.53 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $7.2 | $14.8 | $4.36 | $29.02 |
| Net borrowings | -$0.04 | -$0.04 | -$0.61 | -$0.62 |
| Total cash flows from financing | -$42.79 | $10.84 | -$0.79 | $11.96 |
| Effect of exchange rate | $1.93 | -$3.65 | $1.97 | $2.75 |
| Change in cash and equivalents | -$8.13 | -$30.29 | $91.03 | $114.31 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | $167.65 | $141.56 | -$64.08 | $859.1 |
| Operating activities | ||||
| Depreciation | $104.39 | $101.97 | $108.04 | $105.17 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $207.1 | $196.31 | $197.26 | $189.71 |
| Total cash flows from operations | $159.26 | $175.9 | $304.54 | $85.36 |
| Investing activities | ||||
| Capital expenditures | -$96.69 | -$17.63 | -$95.58 | -$47.15 |
| Investments | -$3.63 | $8.19 | -$246.09 | $17.46 |
| Total cash flows from investing | -$111.24 | -$20.03 | -$366.31 | -$53.62 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $69.35 | $69.33 | $49.19 | $21.91 |
| Net borrowings | -$2.29 | -$2.6 | -$3.04 | $203.84 |
| Total cash flows from financing | -$18.73 | -$18.65 | -$0.05 | $181.12 |
| Effect of exchange rate | $1.31 | $0.03 | -$0.06 | -$1.15 |
| Change in cash and equivalents | $30.6 | $137.25 | -$61.88 | $211.71 |
News
Fundamentals
| Market cap | $15.38B |
|---|---|
| Enterprise value | $15.72B |
| Shares outstanding | 189.78M |
| Revenue | $2.47B |
|---|---|
| EBITDA | $359.85M |
| EBIT | $254.53M |
| Net Income | $205.46M |
| Revenue Q/Q | 8.79% |
| Revenue Y/Y | 13.74% |
| P/E ratio | 74.85 |
|---|---|
| EV/Sales | 6.36 |
| EV/EBITDA | 43.68 |
| EV/EBIT | 61.75 |
| P/S ratio | 6.22 |
| P/B ratio | 3.03 |
| Book/Share | 26.74 |
| Cash/Share | 3.94 |
| EPS | $1.08 |
|---|---|
| ROA | 3.04% |
| ROE | 4.17% |
| Debt/Equity | 0.38 |
|---|---|
| Net debt/EBITDA | 2.92 |
| Current ratio | 2.74 |
| Quick ratio | 1.70 |